CN101171022A - 抑制g蛋白信号传导的组合物和方法 - Google Patents

抑制g蛋白信号传导的组合物和方法 Download PDF

Info

Publication number
CN101171022A
CN101171022A CNA2006800155468A CN200680015546A CN101171022A CN 101171022 A CN101171022 A CN 101171022A CN A2006800155468 A CNA2006800155468 A CN A2006800155468A CN 200680015546 A CN200680015546 A CN 200680015546A CN 101171022 A CN101171022 A CN 101171022A
Authority
CN
China
Prior art keywords
protein
sigk
peptide
subunit
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800155468A
Other languages
English (en)
Chinese (zh)
Inventor
A·V·斯马卡
J·方特
T·博纳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of CN101171022A publication Critical patent/CN101171022A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
CNA2006800155468A 2005-03-07 2006-03-07 抑制g蛋白信号传导的组合物和方法 Pending CN101171022A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65926705P 2005-03-07 2005-03-07
US60/659,267 2005-03-07

Publications (1)

Publication Number Publication Date
CN101171022A true CN101171022A (zh) 2008-04-30

Family

ID=36953955

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800155468A Pending CN101171022A (zh) 2005-03-07 2006-03-07 抑制g蛋白信号传导的组合物和方法

Country Status (7)

Country Link
US (2) US20090221691A1 (enExample)
EP (1) EP1868634A4 (enExample)
JP (1) JP2008537481A (enExample)
CN (1) CN101171022A (enExample)
AU (1) AU2006220652A1 (enExample)
CA (1) CA2600946A1 (enExample)
WO (1) WO2006096690A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523092C (zh) * 2005-05-16 2009-08-05 徐州开达精细化工有限公司 蒽醌型还原染料16,17-二溴紫蒽酮和16,17-二(1’-亚胺基蒽醌基)紫蒽酮及其制备方法
CN105802970A (zh) * 2016-05-30 2016-07-27 东北师范大学 靶向沉默Gβ1的shRNA
CN106908610A (zh) * 2017-03-13 2017-06-30 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
CN108802366A (zh) * 2017-05-04 2018-11-13 中国科学院微生物研究所 一种检测待测样本中目标蛋白的含量的方法
WO2025157155A1 (zh) * 2024-01-23 2025-07-31 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147310A4 (en) * 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
WO2011040564A1 (ja) * 2009-09-30 2011-04-07 千寿製薬株式会社 特定のペプチド化合物を有効成分として含む眼科用剤
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein
CN115368386A (zh) * 2022-08-09 2022-11-22 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种防治骨性关节炎的小分子化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0548165T3 (da) * 1990-09-13 2001-07-16 Univ Duke Ekspression af G-proteinkoblede receptorer i gær
CA2219958A1 (en) * 1998-01-07 1999-07-07 Ekkehard Leberer The g-protein .beta.subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays
US7189519B2 (en) * 1998-08-10 2007-03-13 Stc.Unm Bead-based detection of ligand-GPCR-G protein complexes
PT1139793E (pt) * 1998-12-23 2010-01-19 Sinai School Medicine Inibidores da resposta ao sabor amargo
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
CA2385460A1 (en) * 1999-09-21 2001-03-29 Forsyth Dental Infirmary For Children Rgs10b, a g-protein regulator expressed in osteoclasts
WO2003062393A2 (en) * 2002-01-22 2003-07-31 Bristol-Myers Squibb Company G protein-coupled receptor variants
US20040121330A1 (en) * 2002-12-18 2004-06-24 Feder John N. Novel human G-protein coupled receptor, HGPRBMY4, and methods of use thereof
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523092C (zh) * 2005-05-16 2009-08-05 徐州开达精细化工有限公司 蒽醌型还原染料16,17-二溴紫蒽酮和16,17-二(1’-亚胺基蒽醌基)紫蒽酮及其制备方法
CN105802970A (zh) * 2016-05-30 2016-07-27 东北师范大学 靶向沉默Gβ1的shRNA
CN106908610A (zh) * 2017-03-13 2017-06-30 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
CN106908610B (zh) * 2017-03-13 2018-11-02 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
CN108802366A (zh) * 2017-05-04 2018-11-13 中国科学院微生物研究所 一种检测待测样本中目标蛋白的含量的方法
CN108802366B (zh) * 2017-05-04 2020-01-21 中国科学院微生物研究所 一种检测待测样本中目标蛋白的含量的方法
WO2025157155A1 (zh) * 2024-01-23 2025-07-31 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Also Published As

Publication number Publication date
US20090221691A1 (en) 2009-09-03
US20130116313A1 (en) 2013-05-09
WO2006096690A3 (en) 2007-11-08
EP1868634A2 (en) 2007-12-26
AU2006220652A1 (en) 2006-09-14
EP1868634A4 (en) 2010-10-20
JP2008537481A (ja) 2008-09-18
US8748480B2 (en) 2014-06-10
CA2600946A1 (en) 2006-09-14
WO2006096690A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
Meyrath et al. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
Geppetti et al. Neurogenic inflammation
JP5371567B2 (ja) 感覚伝達に関与するｇタンパク質共役レセプターをコードする核酸
Waters et al. Interactions with LC3 and polyubiquitin chains link nbr1 to autophagic protein turnover
Findeisen et al. RFamide peptides: structure, function, mechanisms and pharmaceutical potential
Sanchez et al. Evaluation and extension of the two-site, two-step model for binding and activation of the chemokine receptor CCR1
EP2282728B1 (en) Modulation of the Vps10p-domain receptors.
JP2009261399A (ja) 感覚伝達に関与するｇタンパク質共役型レセプターをコードする核酸
US8748480B2 (en) Methods for treating opioid tolerance
US20110014128A1 (en) Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same
TW200539867A (en) Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
Wang et al. A novel peptide exerts potent immunosuppression by blocking the two-site interaction of NFAT with calcineurin
JP2000512737A (ja) 試験管内蛍光偏光検定法
US7005272B2 (en) Methods for screening and therapeutic applications of kinesin modulators
Nichols et al. Serotonin receptor signaling and hallucinogenic drug action
White et al. Insights into the regulation of chemokine receptors by molecular signaling pathways: functional roles in neuropathic pain
JP2019507590A (ja) Ｇタンパク質
Wang et al. Pharmacological characterization, cellular localization and expression profile of NPY receptor subtypes Y2 and Y7 in large yellow croaker, Larimichthys crocea
JP2004033211A (ja) 神経ペプチド受容体およびその使用
JP2003530125A (ja) 生物学的物質およびその使用方法
JP4326326B2 (ja) Ｅｐｆ受容体アッセイ、化合物および治療用組成物
Hynes et al. Analysis of chaperonin‐containing TCP‐1 subunits in the human keratinocyte two‐dimensional protein database: further characterisation of antibodies to individual subunits
WO2005121356A1 (ja) 新規スクリーニング方法
KR20070011446A (ko) 개의 냉- 및 멘톨-민감 수용체 1
JP2005516591A (ja) ｅｅ３−タンパク質ファミリーおよびその基になるＤＮＡ配列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080430